Cargando…

The Clinical Impact of Daptomycin Non-susceptible Enterococcus Bacteremia in Hematologic Malignancy

BACKGROUND: Patients with hematologic malignancies are prone to colonization and infection with vancomycin-resistant Enterococcus (VRE), and VRE blood stream infections (BSI) in this population have been associated with a 30-day all-cause mortality approaching 40%. Daptomycin nonsusceptible Enteroco...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Rachael A, Kaye, Keith S, Cutter, Gary, Camins, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631717/
http://dx.doi.org/10.1093/ofid/ofx163.655
_version_ 1783269541270257664
author Lee, Rachael A
Kaye, Keith S
Cutter, Gary
Camins, Bernard
author_facet Lee, Rachael A
Kaye, Keith S
Cutter, Gary
Camins, Bernard
author_sort Lee, Rachael A
collection PubMed
description BACKGROUND: Patients with hematologic malignancies are prone to colonization and infection with vancomycin-resistant Enterococcus (VRE), and VRE blood stream infections (BSI) in this population have been associated with a 30-day all-cause mortality approaching 40%. Daptomycin nonsusceptible Enterococci(DNSE) are on the rise, with institutional rates as high as 15%. The objective of this study was to determine the attributable mortality associated with resistance to daptomycin among VRE isolates. METHODS: We performed a retrospective cohort study of hematologic malignancy patients who developed either DNSE or daptomycin-susceptible VRE bacteremia between January 1, 2008 and December 31, 2016. Categorical variables were analyzed with chi-square or Fisher’s exact test and continuous variables were analyzed with a t-test or Wilcoxon rank sums test when appropriate. A p-value <0.05 was considered significant. RESULTS: 34 cases of DNSE and 65 cases of VRE were identified. There were no significant differences noted in demographic data. At time of bacteremia, both DNSE and VRE cohorts had similar APACHE II scores (medians for DNSE and VRE were 19). The DNSE cohort had longer periods of neutropenia prior to the diagnosis of bacteremia [median 32.1 days vs.. 19.3 days, OR 1.85 95% CI (0.75-1.60)]. Patients with DNSE had a longer time to initiation of appropriate antibiotics (median 3.5 days vs. 2.0 days, P = 0.01). There were similar rates of bone marrow transplantation (53 % of DNSE vs. 51% of VRE), however, DNSE cases were more likely to develop graft vs. host disease [OR 3.6 95% CI (1.07-12.38)]. In the 90-day period prior to bacteremia, daptomycin exposure occurred in only 12 (35.3%) of DNSE cases vs.. 1 (1.5%) VRE case [OR 34.9 95% CI (4.3-284.1)]. Median lengths of stay (LOS) were similarly high in both groups, however, DNSE patients were more likely to have a LOS over 50 days as compared with VRE (P = 0.048). 30-day mortality in the DNSE cohort was 50% compared with 38% in the VRE group (P = 0.12). CONCLUSION: In a retrospective study, the 30-day mortality associated with DNSE bacteremia was 50%. Infection prevention interventions targeting this particular multi-drug-resistant organism are warranted in this vulnerable population. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-5631717
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56317172017-11-07 The Clinical Impact of Daptomycin Non-susceptible Enterococcus Bacteremia in Hematologic Malignancy Lee, Rachael A Kaye, Keith S Cutter, Gary Camins, Bernard Open Forum Infect Dis Abstracts BACKGROUND: Patients with hematologic malignancies are prone to colonization and infection with vancomycin-resistant Enterococcus (VRE), and VRE blood stream infections (BSI) in this population have been associated with a 30-day all-cause mortality approaching 40%. Daptomycin nonsusceptible Enterococci(DNSE) are on the rise, with institutional rates as high as 15%. The objective of this study was to determine the attributable mortality associated with resistance to daptomycin among VRE isolates. METHODS: We performed a retrospective cohort study of hematologic malignancy patients who developed either DNSE or daptomycin-susceptible VRE bacteremia between January 1, 2008 and December 31, 2016. Categorical variables were analyzed with chi-square or Fisher’s exact test and continuous variables were analyzed with a t-test or Wilcoxon rank sums test when appropriate. A p-value <0.05 was considered significant. RESULTS: 34 cases of DNSE and 65 cases of VRE were identified. There were no significant differences noted in demographic data. At time of bacteremia, both DNSE and VRE cohorts had similar APACHE II scores (medians for DNSE and VRE were 19). The DNSE cohort had longer periods of neutropenia prior to the diagnosis of bacteremia [median 32.1 days vs.. 19.3 days, OR 1.85 95% CI (0.75-1.60)]. Patients with DNSE had a longer time to initiation of appropriate antibiotics (median 3.5 days vs. 2.0 days, P = 0.01). There were similar rates of bone marrow transplantation (53 % of DNSE vs. 51% of VRE), however, DNSE cases were more likely to develop graft vs. host disease [OR 3.6 95% CI (1.07-12.38)]. In the 90-day period prior to bacteremia, daptomycin exposure occurred in only 12 (35.3%) of DNSE cases vs.. 1 (1.5%) VRE case [OR 34.9 95% CI (4.3-284.1)]. Median lengths of stay (LOS) were similarly high in both groups, however, DNSE patients were more likely to have a LOS over 50 days as compared with VRE (P = 0.048). 30-day mortality in the DNSE cohort was 50% compared with 38% in the VRE group (P = 0.12). CONCLUSION: In a retrospective study, the 30-day mortality associated with DNSE bacteremia was 50%. Infection prevention interventions targeting this particular multi-drug-resistant organism are warranted in this vulnerable population. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2017-10-04 /pmc/articles/PMC5631717/ http://dx.doi.org/10.1093/ofid/ofx163.655 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Lee, Rachael A
Kaye, Keith S
Cutter, Gary
Camins, Bernard
The Clinical Impact of Daptomycin Non-susceptible Enterococcus Bacteremia in Hematologic Malignancy
title The Clinical Impact of Daptomycin Non-susceptible Enterococcus Bacteremia in Hematologic Malignancy
title_full The Clinical Impact of Daptomycin Non-susceptible Enterococcus Bacteremia in Hematologic Malignancy
title_fullStr The Clinical Impact of Daptomycin Non-susceptible Enterococcus Bacteremia in Hematologic Malignancy
title_full_unstemmed The Clinical Impact of Daptomycin Non-susceptible Enterococcus Bacteremia in Hematologic Malignancy
title_short The Clinical Impact of Daptomycin Non-susceptible Enterococcus Bacteremia in Hematologic Malignancy
title_sort clinical impact of daptomycin non-susceptible enterococcus bacteremia in hematologic malignancy
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631717/
http://dx.doi.org/10.1093/ofid/ofx163.655
work_keys_str_mv AT leerachaela theclinicalimpactofdaptomycinnonsusceptibleenterococcusbacteremiainhematologicmalignancy
AT kayekeiths theclinicalimpactofdaptomycinnonsusceptibleenterococcusbacteremiainhematologicmalignancy
AT cuttergary theclinicalimpactofdaptomycinnonsusceptibleenterococcusbacteremiainhematologicmalignancy
AT caminsbernard theclinicalimpactofdaptomycinnonsusceptibleenterococcusbacteremiainhematologicmalignancy
AT leerachaela clinicalimpactofdaptomycinnonsusceptibleenterococcusbacteremiainhematologicmalignancy
AT kayekeiths clinicalimpactofdaptomycinnonsusceptibleenterococcusbacteremiainhematologicmalignancy
AT cuttergary clinicalimpactofdaptomycinnonsusceptibleenterococcusbacteremiainhematologicmalignancy
AT caminsbernard clinicalimpactofdaptomycinnonsusceptibleenterococcusbacteremiainhematologicmalignancy